Sign inJoin waitlistJoin the waitlist

Jacqueline Barrientos

Chief, Hematologic Malignancies · Mount Sinai Medical Center of Florida, Inc

Credentials: · · · · · ·

History

Hematologic Malignancies Division · Mount Sinai Medical Center of Florida, Inc
Present
Oncology Research · Mount Sinai Medical Center of Florida, Inc
Present
Mount Sinai Medical Center of Florida, Inc
Present

Yale School of Medicine
2011–2013
2008–2011
Pathology-Anatomic and Clinical
Yale-New Haven Hospital
2004–2008
New York Presbyterian Hospital
2001–2004
Weill Cornell Graduate School of Medical Sciences
Ponce Health Sciences University School of Medicine
1997–2001

Research

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
New England Journal of Medicine · 2014 · 1,384 citations
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
New England Journal of Medicine · 2013 · 1,377 citations
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
New England Journal of Medicine · 2014 · 1,369 citations

KR
Kanti Rai
31 papers
Jennifer Brown
25 papers
SO
Susan O'Brien
24 papers
Richard Furman
22 papers
JB
John Byrd
20 papers
Thomas Kipps
20 papers
Paul Barr
19 papers
Steven Coutre
18 papers
Nicholas Chiorazzi
17 papers
JK
Jonathan Kolitz
14 papers
SA
Steven Allen
14 papers
DJ
Danelle James
13 papers

Clinical trials

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
Principal investigator · Terminated · Phase 2
Northwell Health
2017–2018
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2038
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 1
Carna Biosciences, Inc.
2023–2027